BioCryst Pharmaceuticals, Inc. (BCRX): Price and Financial Metrics


BioCryst Pharmaceuticals, Inc. (BCRX): $12.05

0.39 (+3.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BCRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

BCRX Stock Summary

  • Biocryst Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.87% of US listed stocks.
  • With a price/sales ratio of 115.99, Biocryst Pharmaceuticals Inc has a higher such ratio than 96.65% of stocks in our set.
  • As for revenue growth, note that BCRX's revenue has grown -63.53% over the past 12 months; that beats the revenue growth of merely 3.72% of US companies in our set.
  • Stocks that are quantitatively similar to BCRX, based on their financial statements, market capitalization, and price volatility, are CRIS, LOGC, XFOR, MRUS, and PTCT.
  • Visit BCRX's SEC page to see the company's official filings. To visit the company's web site, go to www.biocryst.com.

BCRX Stock Price Chart Interactive Chart >

Price chart for BCRX

BCRX Price/Volume Stats

Current price $12.05 52-week high $14.24
Prev. close $11.66 52-week low $2.75
Day low $11.51 Volume 4,450,700
Day high $12.56 Avg. volume 6,556,769
50-day MA $11.13 Dividend yield N/A
200-day MA $6.86 Market Cap 2.14B

BioCryst Pharmaceuticals, Inc. (BCRX) Company Bio


Biocryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. The company was founded in 1986 and is based in Durham, North Carolina.


BCRX Latest News Stream


Event/Time News Detail
Loading, please wait...

BCRX Latest Social Stream


Loading social stream, please wait...

View Full BCRX Social Stream

Latest BCRX News From Around the Web

Below are the latest news stories about Biocryst Pharmaceuticals Inc that investors may wish to consider to help them evaluate BCRX as an investment opportunity.

Is BCRX Stock A Buy or Sell?

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks initially suffered […]

Yahoo | April 20, 2021

BioCryst slides as State Street cuts stake

Following back-to-back losses on the last two days of the week, BioCryst Pharmaceuticals ([[BCRX]] -6.6%) has witnessed an even sharper decline today after regulatory filings indicated that State Street Corporation has slashed its stake in the company.In an SEC Schedule 13G form filed today, State Street has indicated a stake of ~4.1%...

Seeking Alpha | April 12, 2021

The BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Is Up 421% And Shareholders Are Delighted

While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...

Yahoo | April 8, 2021

BioCryst: Sometimes Good News Isn’t Good Enough

Shares of BioCryst Pharmaceuticals (BCRX) slumped nearly 17% this week. That's kind of surprising, considering that the company released positive data on its paroxysmal nocturnal hemoglobinuria (a rare blood disease that can cause anemia, blood clots, and impaired bone marrow function) inhibitor, BCX9930. According to the company, the latest data show that the drug "was safe and generally well-tolerated" in clinical trials, and "significantly increased hemoglobin and reduced transfusions in an ongoing dose-ranging trial." And yet, as RBC Capital analyst Brian Abrahams explains, good is not always quite good enough.

TipRanks Team on TipRanks | March 24, 2021

BioCryst Technical Levels To Watch

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX ) announced results from a dose-ranging trial evaluating BCX9930 in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients and PNH patients with an inadequate response to C5 inhibitors. The stock was down 7.3% at $12.27 at last check. BioCryst has a market cap of $2.25 billion and a public float of 175 million shares. BioCryst Short Term Chart Analysis: Above, the 5-minute chart on BioCryst shows the stock has built higher lows into a resistance … Full story available on Benzinga.com

Benzinga | March 22, 2021

Read More 'BCRX' Stories Here

BCRX Price Returns

1-mo 14.43%
3-mo 30.84%
6-mo 224.80%
1-year 269.63%
3-year 147.94%
5-year 249.28%
YTD 61.74%
2020 115.94%
2019 -57.25%
2018 64.36%
2017 -22.43%
2016 -38.66%
Page generated in 1.152 seconds.